OOIR: Observatory of International Research

Papers

(The TQCC of Therapeutic Advances in Drug Safety is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-07-01 to 2026-07-01.)

Article	Citations
Development and psychometric assessment of self-reported patient medication safety scale (SR-PMSS)	40
Survival outcomes of beta-blocker usage in HER2-positive advanced breast cancer patients: a retrospective cohort study	32
Adverse drug reactions associated with glycyrrhiza-containing Chinese patent medicines: a literature-based analysis of individual case reports and clinical trials	29
Association between number of medications and indicators of potentially inappropriate polypharmacy: a population-based cohort of older adults in Quebec, Canada	24
Patient-centered pharmacovigilance: priority actions from the inherited bleeding disorders community	24
Acceptability of a cross-sectoral hospital pharmacist intervention for patients in transition between hospital and general practice: a mixed methods study	22
Enhancing pharmacovigilance for robust drug safety monitoring: addressing underreporting and collaborative solutions	19
Methotrexate use and risk of abnormal alanine aminotransferase elevation in children with rare inflammatory diseases: a self-controlled case series analysis using a pediatric electronic health record	17
Factors related to dosing frequency and route of administration in methotrexate intolerance among patients with rheumatoid arthritis: a cross-sectional study	17
Medication errors by caregivers in the homes of children discharged from a pediatric department in Ghana	16
Adverse events associated with statin co-use in breast cancer patients: a disproportionality analysis based on the FDA Adverse Event Reporting System	15
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database	15
Semaglutide: a gendered phenomenon—women’s increased vulnerability to adverse drug reactions in the global weight loss trend	15
Understanding, readiness, and response of healthcare professionals in combating falsified medical products in Eritrea: a population-based survey	12
Prevalence of potentially inappropriate medication use and its association with hospitalization among older adults with chronic disease in the Amhara region, Ethiopia: a multicenter prospective cohort	12
Incidence of antibody–drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis	12
A critical opinion-based review of hospital pharmacy compounding with respect to the risk of leachable substances due to the off-label use of plastic primary packaging	12
Machine learning risk prediction models for medication harm in hospitalised adult patients	12
Disparities and trends in drug-related adverse reaction mortality in the United States, 1999–2020	12
Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling	12
Complex chronic adverse events following immunization: a systemic critique and reform proposal for vaccine pharmacovigilance	11
Exploring the community pharmacist’s knowledge, attitude, and practices regarding adverse drug reactions and its reporting in the United Arab Emirates: a survey-based cross-sectional study	10
Implementation of electronic distribution of Direct Healthcare Professional Communications by the Danish Medicines Agency: a survey study of physicians’ experiences and preferences	10
Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review	10
The American Program in Pharmacovigilance (Am2P): a new accredited online training program in pharmacovigilance and pharmacoepidemiology	9

Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case–control study	9
Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug–supplement interaction	9
Safety monitoring of oral iron supplements in pregnant women with anemia: a multi-center observational clinical study	9
Impact of social determinants of health on safety of patients in device clinical trials conducted at a safety-net hospital	8
The evolution of the Pharmacovigilance department in the pharmaceutical industry: results of an Italian national survey	8
Drug recall, its frequencies and conclusion: a retrospective secondary analysis involving 2-year publicly available data from Nepal	8
Data mining results for reduction of adverse drug–drug interaction events in older adults are clinically applicable	8
Artificial intelligence in drug development: reshaping the therapeutic landscape	7
Impact of risk communication on patient’s safety during the pandemic	7
Treating hearts and minds: adverse cardiovascular effects of psychiatric medications	7
Integration of pre‑existing cardiovascular comorbidity into CDK4/6 inhibitor selection for breast cancer	7
A hybrid simulation model of HIV program interventions: from transmission behavior to macroeconomic impacts	6
Navigating pharmacokinetic and pharmacodynamics challenges of β-lactam antibiotics in patients with low body weight: efficacy, toxicity, and dosage optimization	6
Machine learning studies of drug-induced nephrotoxicity: a scoping review	6
Drug interactions in patients with alcohol use disorder: results from a real-world study on an addiction-specific ward	6
Flow rate accuracy of infusion devices within healthcare settings: a systematic review	6
A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System	6
Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers	6
Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system	6
Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations	6
Probable case of anaphylaxis due to hydrocortisone in a septic shock patient	6
Adverse drug events associated with capecitabine: a real-world pharmacovigilance study based on the FAERS database	6
Efficacy and safety of ciprofol versus propofol for sedation in hysteroscopy: a systematic review and meta-analysis	6
The crucial role of pharmacovigilance in managing infectious diseases in lower and middle-income countries	5
Is there a risk of esketamine misuse in clinical practice?	5
Effect of ciprofol-assisted sedation on tourniquet-related responses in foot and ankle surgery: a randomized clinical trial	5
The real-world safety of lacosamide and perampanel in children: a disproportionality analysis of the FDA Adverse Event Reporting System	5
Seizure following in-office lidocaine administration: a case report on local anesthetic systemic toxicity	5
Analysis of the nature and contributory factors of medication safety incidents following hospital discharge using National Reporting and Learning System (NRLS) data from England and Wales: a multi-met	5
Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries	5
Assessing the risk of tumor lysis syndrome associated with the use of antineoplastic agents: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database	5
Impact of clinical pharmacist involvement on emergency department physicians’ work-time distribution: a comparative analysis	5